Encelto (revakinagene taroretcel-lwey) Coverage for MacTel Type 2
Customize your policy alerts
Sign up for Bluecross Idaho Policy MP 5.01.679 alerts
Get alerted when Policy MP 5.01.679 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical-necessity and coverage requirements for Encelto, a one-time implanted gene and cell therapy for adults with idiopathic macular telangiectasia type 2, subject to applicable Blue Cross of Idaho benefit-plan terms.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.